Spexis AG (SIX: ???)

Polyphor is a clinical stage, Swiss biopharmaceutical company which has discovered and is developing the OMPTA (Outer Membrane Protein Targeting Antibiotics). The OMPTA are potentially the first new class of antibiotics against Gram-negative bacteria to have reached phase III stage in the last 50 years. The company's lead product, murepavadin, (POL7080) is in Phase III development against Pseudomonas aeruginosa - recognized as a critical priority 1 pathogen by WHO. Polyphor is also developing an immuno-oncology candidate, balixafortide (POL6326), which has achieved clinical proof of concept in a Phase Ib/proof of concept study in combination with eribulin in patients with advanced breast cancer, and a pipeline of further preclinical antibiotics based on its OMPTA platform. Polyphor is based in Allschwil near Basel and is listed on the Swiss Stock Exchange (SIX: POLN). *

	Start	2000-10-29 planned merger
	Group	Spexis (Group)
	Predecessor	Polyphor Ltd. (SIX: POLN)
	Industry	antibiotic
	Industry 2	murepavadin (POL7080)
	Person	Batur, Gökhan (Polyphor 202001– promoted to CEO joined 201906 as CCO before Merck (US))
	Person 2	Levett, Hernán (Polyphor 202001 CFO)

	Region	Allschwil BL
	Country	Switzerland
	City	n. a.
		Address record changed: 2021-11-06

Basic data	Employees	C: 51 to 100 (2013-11-04)
	Currency	CHF
	Annual sales	6,545,595 (revenue, total, consolidated (2018) 2018-12-31)
	Profit	-50,920,282 (2018-12-31)
	Cash	113,809,266 (2018-12-31)

		* Document for ï¿½About Sectionï¿½: Polyphor Ltd.. (7/17/18). "Press Release: Polyphor Announces Listing of New Shares Related to the Convertible Loan Facility Agreement with the Wellcome Trust (Ad-hoc Announcement)".

		Record changed: 2021-11-06